Are you someone actively looking for resources to bolster your research on cancer preventive agent development? The NCI PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a peer-reviewed program that supports the preclinical development of innovative interventions and predictive biomarkers for cancer prevention and interception towards clinical applications in high-risk populations. All interested researchers from academia, industry, non-profits, and government with innovative ideas in precision cancer prevention are encouraged to apply.

Deadline: Monday, July 8, 2024.

PREVENT’s current research priority areas are:

• Immunoprevention
• Chemoprevention
• Clinically translatable, response-predictive biomarkers

For more information on Program support, types of supported projects, and the application visit the PREVENT web page.

The latest NCI Cancer Currents blog – about a new blood test that accurately detects pancreatic cancer – features DCP’s Matt Young, Ph.D., co-lead program director of NCI’s Pancreatic Cancer Detection Consortium, which funded the research.

“Pancreatic cancer is devastating,” said Young. “Once you’re diagnosed [with late-stage disease], you usually have 3 to 6 months to live. So, anything we can do to change that is important.”

Read the blog.

Wednesday, May 29
Noon-1:00 p.m. ET
Advance registration required

Chemtai Mungo, M.D., M.P.H., assistant professor of obstetrics and gynecology at University of North Carolina-Chapel Hill, will give a talk titled, “Feasibility of Self-Administered, Intravaginal Therapies for Cervical Precancer Treatment in Low- and Middle-Income Countries.”

Learn more about the seminar series.

Wednesday, June 12
3:00-4:00 p.m. ET
Advance registration required

Drew Weissman, M.D., Ph.D., a world-renowned physician, and researcher at Penn Medicine, will give a talk on nucleoside modified mRNA-LNP therapeutics in cancer research, as part of the NCI DCP IIG. In 2023, Dr. Weissman, along with Dr. Katalin Kariko, received the Nobel Prize in Physiology for mRNA vaccine discoveries that led to effective COVID vaccines.

Learn more about the seminar.

Tuesday, June 18
3:00-4:00 p.m. ET
Advance registration required

Join us to hear Paola Alberti, M.D., Ph.D., from the School of Medicine and Surgery at University of Milano-Bicocca, will discuss methods for studying chemotherapy-induced peripheral neuropathy (CIPN) in preclinical studies and building collaborative translational teams. Ellen M. Lavoie Smith, Ph.D., M.S.N., R.N., AOCN®, FAAN, from the University of Alabama at Birmingham School of Nursing, will then address methods and techniques for assessing CIPN in clinical trials.

Learn more about the webinar series.

Tuesday, June 25 – Thursday, June 27
Boston, MA
Advance registration required

The American Cancer Society, NCI, and Cancer Research UK are launching their first annual conference on prevention research that aims to create a multidisciplinary cancer prevention research community, spark new collaborations and ideas, and advance cancer prevention.

Registration deadline: June 11

For more information, including meeting agenda, speakers, and hotel, visit the Cancer Prevention Research Conference event website.

NCI invites applications from current NIH grant awardees or cooperative agreement program participants interested in collaborating with the NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Specialized Centers to support CAP-IT Program research. All potential applicants are encouraged to contact the NCI Program Directors to discuss the planned collaboration and application.

NOT-CA-24-047

Expires: June 14, 2024

This Notice of Special Interest (NOSI) from NCI encourages applications from early career scientists conducting early translational research in cancer prevention, interception, screening, and early detection within the mission of DCP for the Mentored Research Scientist Development Award (K01).

NOT-CA-24-023

Expires: May 8, 2029

View other career development funding opportunities from DCP, NCI, and NIH.